The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Slide banner

225Ac-GPC3 (BAY 3547926)

See how this compound is being investigated across Bayer’s oncology pipeline

Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.

BAY_3547926_(²²⁵Ac-GPC3)_sqrt

Compound Overview

Liver cancer, including hepatocellular carcinoma (HCC), is the third-leading cause of cancer-related deaths in the world, with almost 900,000 new cases annually.1 Oncofetal protein glypican 3 (GPC3) is a membrane-associated proteoglycan that is overexpressed in 70%–75% of HCC lesions, making it an attractive target for targeted radionuclide therapy.1 225Ac-GPC3 (BAY 3547926) is an investigational, targeted alpha radiopharmaceutical that comprises a high-affinity antibody linked to a macropa chelator that is radiolabeled with actinium-225.1 225Ac-GPC3 (BAY 3547926) is being developed to treat tumors expressing GPC3 in patients with advanced HCC.1,2

Tumor Type

Liver cancer

Area of Research

Targeted radionuclide therapy

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Liver Cancer

I

Now Enrolling

A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC) (BANTAM-01)

NCT06764316

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.